GlaxoSmithKline ($GSK) put up $50 million of a $250 million life sciences fund, assembled by San Mateo, CA-based Sanderling Ventures, to help fill a geographic gap in their strategy to seed new biotech startups. Report
FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Join 100,000+ pharma industry leaders who get FiercePharma via daily email. Click here to get your free weekly email briefing today!